Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;46(6):1326-1343.
doi: 10.1016/j.ultrasmedbio.2020.01.027. Epub 2020 Mar 11.

Microbubble Agents: New Directions

Affiliations
Review

Microbubble Agents: New Directions

Eleanor Stride et al. Ultrasound Med Biol. 2020 Jun.

Abstract

Microbubble ultrasound contrast agents have now been in use for several decades and their safety and efficacy in a wide range of diagnostic applications have been well established. Recent progress in imaging technology is facilitating exciting developments in techniques such as molecular, 3-D and super resolution imaging and new agents are now being developed to meet their specific requirements. In parallel, there have been significant advances in the therapeutic applications of microbubbles, with recent clinical trials demonstrating drug delivery across the blood-brain barrier and into solid tumours. New agents are similarly being tailored toward these applications, including nanoscale microbubble precursors offering superior circulation times and tissue penetration. The development of novel agents does, however, present several challenges, particularly regarding the regulatory framework. This article reviews the developments in agents for diagnostic, therapeutic and "theranostic" applications; novel manufacturing techniques; and the opportunities and challenges for their commercial and clinical translation.

Keywords: Cavitation nuclei; Microbubbles; Nanodroplets; Theranostic; Ultrasound contrast agents.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest TB and SC are full time employees of Bracco Suisse. The other authors are hold full time academic positions and have the following company affiliations: ES is a founder and non-executive director of SonoTarg Ltd.; MB is a founder and chief scientific officer of Respirogen Inc.

Publication types

LinkOut - more resources